A Validated Mathematical Model of Tumor Growth Including Tumor–Host Interaction, Cell-Mediated Immune Response and Chemotherapy

We consider a dynamical model of cancer growth including three interacting cell populations of tumor cells, healthy host cells and immune effector cells. The tumor–immune and the tumor–host interactions are characterized to reproduce experimental results. A thorough dynamical analysis of the model is carried out, showing its capability to explain theoretical and empirical knowledge about tumor development. A chemotherapy treatment reproducing different experiments is also introduced. We believe that this simple model can serve as a foundation for the development of more complicated and specific cancer models.

[1]  J. Bartek,et al.  The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.

[2]  Ami Radunskaya,et al.  The dynamics of an optimally controlled tumor model: A case study , 2003 .

[3]  A. Radunskaya,et al.  Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .

[4]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[5]  M. Eigen,et al.  What is a quasispecies? , 2006, Current topics in microbiology and immunology.

[6]  Doron Levy,et al.  The dynamics of drug resistance: a mathematical perspective. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  John A. Adam,et al.  A mathematical model of cycle-specific chemotherapy , 1995 .

[8]  D. Kirschner,et al.  Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.

[9]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[10]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[11]  Gouhei Tanaka,et al.  A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer , 2008, J. Nonlinear Sci..

[12]  S N Gardner,et al.  A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.

[13]  E. T. Gawlinski,et al.  A reaction-diffusion model of cancer invasion. , 1996, Cancer research.

[14]  M. L. Martins,et al.  Reaction-diffusion model for the growth of avascular tumor. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.

[15]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[16]  P. Hein,et al.  Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.

[17]  Chiara Brignole,et al.  Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. , 2006, Cancer research.

[18]  Frank Nani,et al.  A chemotherapy model for the treatment of cancer with metastasis , 2002 .

[19]  L. D. de Pillis,et al.  A cellular automata model of tumor-immune system interactions. , 2006, Journal of theoretical biology.

[20]  L. D. Pillis,et al.  A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth , 2005 .

[21]  R. Hiramoto,et al.  Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma. , 1974, Cancer research.

[22]  Shea N Gardner,et al.  Modeling multi-drug chemotherapy: tailoring treatment to individuals. , 2002, Journal of theoretical biology.

[23]  M A Nowak,et al.  What is a quasispecies? , 1992, Trends in ecology & evolution.

[24]  Nicola Bellomo,et al.  On the foundations of cancer modelling: Selected topics, speculations, and perspectives , 2008 .

[25]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[26]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[27]  M. Trivett,et al.  Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.

[28]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[29]  M. L. Martins,et al.  Morphology transitions induced by chemotherapy in carcinomas in situ. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.